Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983;16(2):98-100.
doi: 10.1007/BF00199239.

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

I R Mackay, M D Goodyear, C Riglar, J Penschow

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

I R Mackay et al. Cancer Immunol Immunother. 1983.

Abstract

Natural killer (NK) cell activity and antibody-dependent (K) cell activity were studied sequentially in 30 patients with early node-positive breast cancer entered into an adjuvant chemotherapy trial. The drugs used were melphalan, and melphalan with methotrexate, given for 12 months. Estimations were made 3-monthly during chemotherapy, and then at 15 and 24 months to assess recovery. Mean values for NK-cell activity during chemotherapy were significantly lower than the mean pre-chemotherapy baseline value at all time-points from 3 to 15 months, but there was recovery by 24 months. Mean values for K-cell activity during chemotherapy did not appear to differ from the mean pre-chemotherapy value, but variability in individual values was high. Over a 4-year follow-up period, a comparison of 16 patients who did not develop recurrent breast cancer with 14 who did showed that NK-cell activity was significantly lower in the latter group 12 months after the start of chemotherapy.

PubMed Disclaimer

References

    1. Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U. Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol. 1978;5:450. - PubMed
    1. Cunningham-Rundles S, Filippa DA, Braun DW, Antonelli P, Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst. 1981;67:585. - PubMed
    1. Eremin O. NK cell activity in the blood, tumour-draining lymph nodes and primary tumours of women with mammary carcinoma. In: Herberman RB, editor. Natural cell-mediated immunity against tumors. New York: Academic Press; 1980. pp. 1011–1029.
    1. Fisher B, Sherman B, Rockette H, Redman C, Margolese R, Fisher ER. L-phenyl alanine mustard (L-PAM) in the management of pre-menopausal patients with primary breast cancer. Lack of depression of disease-free survival with depression of ovarian function. Cancer. 1979;44:847. - PubMed
    1. Forbes JT, Greco FA, Oldham RK. Human natural cell-mediated cytotoxicity. II. Levels in neoplastic disease. Cancer Immunol Immunother. 1981;11:147.

Publication types

MeSH terms

LinkOut - more resources